Adenosine A2A receptor antagonists provide a promising nondopaminergic approach to the
treatment of Parkinson's disease (PD). Initial clinical trials of A2A antagonists targeted PD …

The adenosine A2A receptor has recently emerged as a leading non-dopaminergic
therapeutic target for Parkinson's disease, largely due to the restricted distribution of the …

Laboratory and clinical experience have pointed to the value of targeting motor pathways
emerging from the striatum to treat problems arising in advanced Parkinson's disease (PD) …

KW-6356 is a novel adenosine A2A (A2A) receptor antagonist/inverse agonist, and its
efficacy as monotherapy in Parkinson's disease (PD) patients has been reported …

The 8-substituted 9-ethyladenine derivatives: 8-bromo-9-ethyladenine (ANR 82), 8-ethoxy-9-
ethyladenine (ANR 94), and 8-furyl-9-ethyladenine (ANR 152) have been characterized in …

Objective Based on new understanding of nondopaminergic pathways involved in
Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist …

During a program to investigate the biochemical basis of side effects associated with the
antimalarial drug mefloquine, the authors made the unexpected discovery that the (−)-(R, S) …

BACKGROUND The present invention relates to substituted 5-amino pyrazolo-4, 3-e-1, 2, 4-
triazolo 1, 5-cpyrimidine adenosine A receptor antagonists, the use of Said compounds in …

The antagonistic interaction between adenosine and dopamine receptors could have
important pathophysiological and therapeutic implications in Parkinson's disease (PD). The …

There is now growing interest in the functional role of adenosine A2A receptors. Their
distribution within the brain is restricted in the basal ganglia, particularly abundant in the …